ClinicalXchange Oncology podcasts

Presenter:Philip R. Muskin MD, MA, DLFAPAProfessor of PsychiatryColumbia University Irving Medical CenterSenior Consultant in Consultation-Liaison PsychiatryNew York-Presbyterian HospitalNew York, NYChronic medical illnesses such as cancer are characterized by a notably increased prevalence of depression. Furthermore, several challenges may arise in managing the depression in these patients, given their anti-cancer regimens. Here, we present a short learning module that will help clinicians better recognize and diagnose patients with cancer who may also have depression, as well as develop treatment plans tailored to their concomitant anti-cancer regimens.Follow along with the slideset located here:https://bit.ly/3Auicb2 

Presenter:Hope S. Rugo MDProfessor of MedicineUniversity of CaliforniaSan Francisco Comprehensive Cancer CenterTNBC comprises approximately 15% of newly diagnosed breast cancer cases and is defined by being estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor receptor 2-negative. This breast cancer subtype is very aggressive, with a median overall survival slightly greater than 1 year. Furthermore, treatment options are limited. New and innovative therapies are being evaluated in patients to improve their outcomes, including progression-free survival and time to deterioration in health-related quality of life. Here, we present an expert-led review on current standards of care, as well as novel and emerging treatment regimens that are in the pipeline for approval by the United States Food and Drug Administration and/or under investigation.Follow along with the slideset located here:https://bit.ly/3krD3Gj 

Presenter:Gail J. Roboz MDProfessor of MedicineDirector, Clinical and Translational Leukemia ProgramWeill Medical College of Cornell UniversityNew York-Presbyterian HospitalNew York, New York, United StatesThis brief program will begin with a review of NCCN Guidelines® Recommendations for the treatment of AML in individuals 60 years of age or older. Next, the results of the BRIGHT AML 1003 trial comparing glasdegib + LDAC to LDAC alone, the VIALE-A trial comparing venetoclax + azacitidine vs azacitidine alone, and a comparison of CPX-351 vs standard of care cytarabine + daunorubicin (7 + 3 regimen) for induction and consolidation, will be reviewed. The faculty will discuss FLT3 and IDH inhibitor approvals for AML, IDK differentiation syndrome, and measuring MRD in AML. Finally, results of a trial examining oral azacitidine and a meta-analysis of 5 trials examining gemtuzumab ozogamicin will be reviewed.https://www.clinical-care.org/resource-center-details/using-available-evidence-and-guidelines-for-managing-an-evolving-aml-treatment-paradigmFollow along with the slideset located here:https://bit.ly/3lJNHYC